News & Publications

Dr Jaap Kampinga appointed as Chief Scientific Officer

Immodulon, the immuno-oncology company, is pleased to announce the appointment of Dr Jaap Kampinga as its Chief Scientific Officer. He will work closely with COO Graham Burton and the Immodulon Board to realise the company’s potential as leaders in cancer...

read more

The impact of IMM-101 on Dendritic cells (II)

Further data from an ongoing collaboration between the laboratory of Prof. Andrew MacDonald at Manchester Collaborative Centre for Inflammation Research (University of Manchester, Manchester, UK) and Immodulon Therapeutics on the effects of IMM-101 (a...

read more

IMM-201 & CU-Boulder Research

Results from pre-clinical research conducted at the University of Colorado Boulder in the USA led by Dr Chris Lowry, as part of an agreement with Immodulon to test Mycobacterium vaccae NCTC11659 in a variety of laboratory models of mental...

read more

On the search for clinical biomarkers

In this review, Immodulon in collaboration with Myriad Rule Based Medicine (USA) describes the TruCulture® system. This technology applied to small whole blood sample permits investigation of immunological activity following immune stimulation...

read more

The impact of IMM-101 on Dendritic cells (I)

A collaboration between the laboratory of Prof. Andrew MacDonald at Manchester Collaborative Centre for Inflammation Research (University of Manchester, Manchester, UK) and Immodulon Therapeutics investigating the effects of IMM-101 (a...

read more

The impact of IMM-101 on cells of the immune system

A collaboration between the laboratory of Prof. George Bahr at the University of Balamand, Lebanon and Immodulon Therapeutics investigating the effects of IMM‑101 (a heat-killed whole cell preparation of Mycobacterium obuense NCTC13365) on...

read more

Study No. IMM-101-008 (Ongoing)

An Open Label Long‑term Follow‑up Study for Patients with Melanoma who were previously Enrolled in the Phase I Study IMM‑101‑001Phase I EudraCT No. 2011-003967-31 ClinicalTrials.gov NCT01559818 Following the completion of study IMM‑101‑001,...

read more